A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

Inclusion Criteria: * Subjects with early to mid HD, i.e., genetically confirmed HD (cytosine, adenine, guanine \[CAG\] codon repeat length ≥ 36), motor signs of HD, and a Total Functional Capacity Subscale Score (TFC) ≥ 7 * Body mass index between 18 and 31 kg/m2 inclusive * All subjects must have a body weight greater than 50 kg * Female subjects must be surgically sterile, postmenopausal, or willing to practice a highly effective method of contraception. All female participants must be nonlactating and nonpregnant. Male subjects must agree to use a reliable method of birth control during the study and for 3 months after the last dose of study drug. * Capable of providing informed consent * MMSE ≥24 * Subjects must have a live-in competent observer Exclusion Criteria: * Participation in a study or received an investigational drug within 30 days of the Baseline Visit * Any prior or concomitant use of compounds suspected of interfering with protein acetylation * Any concomitant use of medications that are known inhibitors of CYP450 enzymes or substrates of CYP1A2 at the time of enrollment * Suicide risk, as determined by meeting either of the following criteria: a) a suicide attempt within the past year or suicidal ideation within 60 days of the Screening Visit; b) Significant risk of suicide, as judged by the Investigator * Subjects with MMSE \< 24 * Subjects with presence of clinically significant psychosis and/or confusional states, in the opinion of the Investigator * Subjects with clinically significant laboratory or ECG abnormalities at Screening or Baseline * Subjects with clinically relevant hematologic, hepatic, cardiac, or renal disease * Subjects with a current or past (within the last 12 months) history of epilepsy or seizures * A medical history of infection with human immunodeficiency virus, hepatitis C, and/or hepatitis B * Subjects with a history of substance abuse within the past 12 months * Female subjects who are pregnant or breastfeeding * Known allergy to any ingredient in the study drug * A history of malignancy of any type within 2 years prior to Screening. A history of surgically-excised nonmelanoma skin cancers is permitted. * Any relevant condition, behavior, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the subject unsuitable for entry into the study